|
Reuters OSI, Millennium, Onyx shares seen rising-Barron`s Sunday April 18, 4:35 pm ET NEW YORK, April 18 (Reuters) - Stocks of small biotechnology companies are poised to advance beyond its recent run-up on prospects about licensing deals and acquisitions, Barron`s reported in its latest issue. ADVERTISEMENT Big pharmaceutical groups are looking for small, promising biotech companies to drive growth as some of their top-selling drugs lose patent protection in the next couple of years, according to the article. Morgan Stanley biotech analyst Steve Harr told Barron`s he is focusing on companies with new treatments for the toughest medical problems, like cancer. Among them are OSI Pharmaceuticals Inc. (NasdaqNM:OSIP - News), Millennium Pharmaceuticals Inc.(NasdaqNM:MLNM - News) and Onyx Pharmaceuticals Inc. (NasdaqNM:ONXX - News). Harr also anticipates that a successful treatment for an eye disease could boost the stock of Eyetech Pharmaceuticals Inc. (NasdaqNM:EYET - News) to $42. Eyetech closed at $33.49 on Friday. On Friday Nasdaq trade, OSI Pharmaceuticals closed at $36.20, Millennium ended at $16.88, and Onyx finished at $43.25. Harr said he does not own shares in the biotech companies he covers, but his firm has done investment banking work for them. |
|
| aus der Diskussion: | onyx pharmaceut. im juhu musterdepot! |
| Autor (Datum des Eintrages): | panik (19.04.04 00:05:46) |
| Beitrag: | 99 von 229 (ID:12785240) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |